Literature DB >> 10490979

Phosphorylated peptides can be transported by TAP molecules, presented by class I MHC molecules, and recognized by phosphopeptide-specific CTL.

M H Andersen1, J E Bonfill, A Neisig, G Arsequell, I Sondergaard, G Valencia, J Neefjes, J Zeuthen, T Elliott, J S Haurum.   

Abstract

CTL recognize short peptide fragments presented by class I MHC molecules. In this study, we examined the effect of phosphorylation on TAP transport, binding to class I MHC molecules, and recognition by CTL of peptide fragments from known phosphorylated oncogene proteins or virus phosphoproteins. We show that phosphopeptides can be efficiently transported from the cytosol to the endoplasmic reticulum by the TAP. Furthermore, we show that phosphorylation can have a neutral, negative, or even a positive effect on peptide binding to class I MHC. Finally, we have generated phosphopeptide-specific CTL that discriminate between the phosphorylated and the nonphosphorylated versions of the peptide. We conclude that phosphopeptide-specific CTL responses are likely to constitute a subset of the class I MHC-restricted CTL repertoire in vivo.

Mesh:

Substances:

Year:  1999        PMID: 10490979

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  40 in total

1.  Targeting phosphorylated p53 to elicit tumor-reactive T helper responses against head and neck squamous cell carcinoma.

Authors:  Kenzo Ohara; Takayuki Ohkuri; Takumi Kumai; Toshihiro Nagato; Yui Nozaki; Kei Ishibashi; Akemi Kosaka; Marino Nagata; Shohei Harabuchi; Mizuho Ohara; Kensuke Oikawa; Naoko Aoki; Yasuaki Harabuchi; Esteban Celis; Hiroya Kobayashi
Journal:  Oncoimmunology       Date:  2018-08-01       Impact factor: 8.110

2.  Indoleamine 2,3-dioxygenase specific, cytotoxic T cells as immune regulators.

Authors:  Rikke Baek Sørensen; Sine Reker Hadrup; Inge Marie Svane; Mads Christian Hjortsø; Per Thor Straten; Mads Hald Andersen
Journal:  Blood       Date:  2010-11-15       Impact factor: 22.113

3.  Increased diversity of the HLA-B40 ligandome by the presentation of peptides phosphorylated at their main anchor residue.

Authors:  Miguel Marcilla; Adán Alpízar; Manuel Lombardía; Antonio Ramos-Fernandez; Manuel Ramos; Juan Pablo Albar
Journal:  Mol Cell Proteomics       Date:  2013-12-23       Impact factor: 5.911

Review 4.  A peptide's perspective on antigen presentation to the immune system.

Authors:  Jacques Neefjes; Huib Ovaa
Journal:  Nat Chem Biol       Date:  2013-12       Impact factor: 15.040

Review 5.  Functional regulation of immunoproteasomes and transporter associated with antigen processing.

Authors:  L Y Hwang; P T Lieu; P A Peterson; Y Yang
Journal:  Immunol Res       Date:  2001       Impact factor: 2.829

Review 6.  Insights into MHC class I antigen processing gained from large-scale analysis of class I ligands.

Authors:  Gabor Mester; Vanessa Hoffmann; Stefan Stevanović
Journal:  Cell Mol Life Sci       Date:  2011-03-09       Impact factor: 9.261

7.  A post-translational modification of nuclear proteins, N(G),N(G)-dimethyl-Arg, found in a natural HLA class I peptide ligand.

Authors:  J Yagüe; J Vázquez; J A López de Castro
Journal:  Protein Sci       Date:  2000-11       Impact factor: 6.725

8.  A Molecular Basis for the Presentation of Phosphorylated Peptides by HLA-B Antigens.

Authors:  Adán Alpízar; Fabio Marino; Antonio Ramos-Fernández; Manuel Lombardía; Anita Jeko; Florencio Pazos; Alberto Paradela; César Santiago; Albert J R Heck; Miguel Marcilla
Journal:  Mol Cell Proteomics       Date:  2016-12-05       Impact factor: 5.911

Review 9.  Lipopeptides: a novel antigen repertoire presented by major histocompatibility complex class I molecules.

Authors:  Daisuke Morita; Masahiko Sugita
Journal:  Immunology       Date:  2016-08-10       Impact factor: 7.397

10.  The immune system strikes back: cellular immune responses against indoleamine 2,3-dioxygenase.

Authors:  Rikke Baek Sørensen; Linda Berge-Hansen; Niels Junker; Christina Aaen Hansen; Sine Reker Hadrup; Ton N M Schumacher; Inge Marie Svane; Jürgen C Becker; Per thor Straten; Mads Hald Andersen
Journal:  PLoS One       Date:  2009-09-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.